✦ LIBER ✦

Plasma fibrinogen: Its relationship with oral contraception, the menopause, and hormone replacement therapy

✍ Scribed by Amanda J. Lee; Gordon D.O. Lowe; William C.S. Smith; Tunstall-Pedoe Hugh

Book ID: 107740478
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 240 KB
Volume: 25
Category: Article
ISSN: 0009-9120
DOI: 10.1016/0009-9120(92)80026-d

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Does hormone replacement therapy and use

Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer?

✍ Fatima Birch-Johansen; Allan Jensen; Anne Braae Olesen; Jane Christensen; Anne T 📂 Article 📅 2012 🏛 Springer Netherlands 🌐 English ⚖ 223 KB

Oral contraceptives, menopausal hormone

Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study

✍ Yani Lu; Sophia S. Wang; Jane Sullivan-Halley; Ellen T. Chang; Christina A. Clar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 140 KB 👁 1 views

We examined oral contraceptive (OC) and menopausal hormonal therapy (MHT) use in relation to risk of B-cell non-Hodgkin lymphoma (NHL). Women under age 85 years participating in the California Teachers Study with no history of hematopoietic cancer were followed from 1995 through 2007. A total of 516

Hormone replacement therapy and breast c

Hormone replacement therapy and breast cancer in former users of oral contraceptives—The Norwegian Women and Cancer study

✍ Eiliv Lund; Kjersti Bakken; Vanessa Dumeaux; Vegard Andersen; Merethe Kumle 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 66 KB 👁 2 views

## Abstract Combined estrogen–progestin menopausal therapy (HRT) and combined estrogen–progestin contraceptives (OC) both increase breast cancer risk during current use and a few years after. We investigated risk of breast cancer in women who were users of HRT dependant on former history of OC use